Chen, X., Du, Z., Zhang, Z., & Chen, D. (2025). D-Chiro Inositol Supplementation and the Occurrence of Gestational Diabetes: A Randomized Controlled Trial in China. Food science & nutrition. https://doi.org/10.1002/fsn3.4601
Chen X, Du Z, Zhang Z, Chen D. D-Chiro Inositol Supplementation and the Occurrence of Gestational Diabetes: A Randomized Controlled Trial in China. Food science & nutrition. 2025. doi:10.1002/fsn3.4601
Chen, Xinning, et al. "D-Chiro Inositol Supplementation and the Occurrence of Gestational Diabetes: A Randomized Controlled Trial in China." Food science & nutrition, 2025.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Open Access
Free full text on PubMed Central (PMC11717031)
RRM Academy Synopsis
High-Risk Women Had Less Gestational Diabetes on D-Chiro Inositol
A randomized placebo trial of 276 high-risk pregnant women in China found that about 25 out of 100 women taking D-chiro inositol developed gestational diabetes, against about 38 out of 100 on placebo. Babies born to women in the inositol group had a lower mean birth weight.
Key Findings
Gestational diabetes occurred in 30 of 121 women (24.8%) taking D-chiro inositol and 45 of 118 (38.1%) taking placebo (hazard ratio 0.54, 95% CI 0.31, 0.93).
Newborns weighed a mean 3341.6 g with inositol and 3487.9 g with placebo (p = 0.011). Macrosomia occurred in 6 of 114 (5.3%) and 14 of 112 (12.5%) (p = 0.055).
Only the 43 women with PCOS or diabetes in the family showed a significant reduction in gestational diabetes (HR 0.27, 95% CI 0.07, 0.99).
Maternal weight gain, hypertension disorders, preterm birth and delivery mode did not differ between groups. No participant reported side effects from the drugs.
Interpretation
The study is a double-blind randomized trial at two hospitals in Zhejiang Province. It assigned 139 women to inositol and 137 to placebo at 12 to 16 weeks of pregnancy. Each woman carried a risk factor, such as age 35 or older, higher pre-pregnancy weight, earlier gestational diabetes, or PCOS (Polyendocrine Metabolic Ovarian Syndrome, PMOS). Results cover women who completed glucose testing or delivery. The authors note that heavy loss to follow-up ruled out an intention-to-treat analysis. Earlier trials enrolled European women and mostly tested myo-inositol.
RRM Context
Inositol acts on insulin signaling, a pathway involved in PCOS and in gestational diabetes. The clearest reduction appeared in women with PCOS or diabetes in the family. Restorative reproductive medicine looks for metabolic causes and addresses those causes early. This trial adds pregnancy data on D-chiro inositol, which earlier research studied less than myo-inositol.
Our editorial summary of this paper, not the article's abstract.
Abstract
To investigate the effect of D-chiro inositol (DCI) supplementation on perinatal outcomes in pregnant women at high risk of gestational diabetes mellitus (GDM), we conducted a prospective, randomized, placebo-controlled study. Eligibility criteria included women aged ≥ 35 years old, with a pre-pregnancy body mass index ≥ 24 kg/m2, having a family history of type 2 diabetes, having a history of GDM, polycystic ovary syndrome, or a history of delivering macrosomia infants. Participants who were recruited at a gestational age of 12-16 weeks, were randomly to receive either DCI 500 mg twice daily or to receive a placebo for 12 weeks. Outcome measured included the occurrence of GDM and other perinatal outcomes. Between 2020 and 2022, 276 participants were enrolled, with 139 in the DCI Group and 137 in the Control Group. Occurrence of GDM was significantly lower in the DCI group compared to that in placebo group (24.8% vs. 38.1%, p = 0.027). A significant difference was observed in the 1-h glycemia during the oral glucose tolerance test (OGTT) (8.35 ± 1.55 vs. 8.81 ± 1.85, p = 0.043), however, no significant differences in the fasting glucose level or 2-h glycemia between the two groups. The mean birth weight of newborns in the control group was significantly heavier than in the DCI group (3487.9 ± 437.7 g vs. 3341.6 ± 420.1 g, p = 0.011). Therefore, DCI supplementation in early pregnancy can reduce the occurrence of GDM in women at high risk.